
Issuance of new shares in connection with a directed issue

Initiator Pharma A/S, company reg. (CVR) no. 37663808, ("Initiator" or the "Company") has today issued new shares in connection with the capital increase directed at Annika Espander, the Company's strategic advisor.

With reference to the company announcement dated 5 July 2022, the Company's share capital has today been increased by a total of nominally DKK 34,999.965 divided into 333,333 shares of nominally DKK 0.105 (the "New Shares") as a result of the directed issue to Annika Espander. The shares have been issued at market value without pre-emption rights for the existing shareholders subject to the board authorisation in article 4b in the Company's articles of association. The capital increase has been registered with the Danish Business Authority.

The New Shares are subject to the same rights as existing shares under the Company's articles of association and is expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872 within a few days.

After the capital increase, the total nominal value of the Company's share capital amounts to nominally DKK 4,924,338.4 divided into 46,898,461 shares of nominally DKK 0.105 each corresponding to 46,898,461 votes.

The Company's updated articles of association have been made available on the Company's website.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90, is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Issuance of new shares in connection with a directed issue